Predictors of achieving and sustaining glycaemic control and weight loss with tirzepatide in individuals with type 2 diabetes and increased cardiovascular risk (SURPASS-4)

被引：0
|
作者：
Kahn, S. E. [1 ,2 ]
Del Prato, S. [3 ]
Pavo, I. [4 ]
Franco, D. R. [5 ]
Zheng, J. [4 ]
Nicolay, C. [4 ]
Hemmingway, A. [4 ]
Wiese, R. J. [4 ]
Pearson, E. R. [6 ]
机构：
[1] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[2] Univ Washington, Seattle, WA USA
[3] St Anna Sch Adv Studies, Pisa, Italy
[4] Eli Lilly & Co, Indianapolis, IN USA
[5] CPCLIN DASA Clin Res Ctr, Sao Paulo, Brazil
[6] Univ Dundee, Dundee, Scotland
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
757
引用
收藏
页码：S362 / S362
页数：1
相关论文
共 50 条
  • [1] Predictors of achieving weight loss ≥15% with tirzepatide in people with type 2 diabetes from SURPASS 1-4
    Malecki, M.
    Batterham, R.
    Sattar, N.
    Levine, J.
    Rodriguez, A.
    Bergman, B.
    Wang, H.
    Ghimpeteanu, G.
    Lee, C.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [2] Sustainability of HbA1c control of tirzepatide vs insulin glargine in people with type 2 diabetes and increased cardiovascular risk: SURPASS-4
    Kahn, S. E.
    Del Prato, S.
    Pavo, I.
    Franco, D. R.
    Yang, Z.
    Wiese, R. J.
    Pearson, E. R.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S284 - S284
  • [3] Sustainability of HbA1c Control of Tirzepatide vs. Insulin Glargine in People with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
    Pearson, Ewan
    Del Prato, Stefano
    Pavo, Imre
    Franco, Denise R.
    Yang, Zhengyu
    Wiese, Russell
    Kahn, Steven E.
    DIABETES, 2022, 71
  • [4] Tirzepatide improves amino acid profile in people with long-standing diabetes and increased cardiovascular risk in the SURPASS-4 trial
    Pirro, V.
    Lin, Y.
    Willency, J. A.
    Abadi, A.
    Wiese, R. J.
    Duffin, K. L.
    Pavo, I.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S313 - S314
  • [5] Tirzepatide reduces serum triglyceride concentrations irrespective of concomitant fibrate use in SURPASS-4 participants with type 2 diabetes at high cardiovascular risk
    Varkonyi, T.
    Del Prato, S.
    Pavo, I.
    Nicolay, C.
    Wiese, R. J.
    Kahn, S. E.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S305 - S305
  • [6] Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
    Del Prato, Stefano
    Kahn, Steven E.
    Pavo, Imre
    Weerakkody, Govinda J.
    Yang, Zhengyu
    Doupis, John
    Aizenberg, Diego
    Wynne, Alan G.
    Riesmeyer, Jeffrey S.
    Heine, Robert J.
    Wiese, Russell J.
    LANCET, 2021, 398 (10313): : 1811 - 1824
  • [7] COMPARED TO INSULIN GLARGINE, TIRZEPATIDE REDUCES THE PREVALENCE OF THE METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK: POST-HOC ANALYSIS OF SURPASS-4
    Nicholls, Stephen J.
    D'Alessio, David
    Wiese, Russell
    Pavo, Imre
    Zeytinoglu, Meltem
    Romera, Irene
    Weerakkody, Govinda J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1628 - 1628
  • [8] Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4
    Malecki, Maciej T.
    Batterham, Rachel L.
    Sattar, Naveed
    Levine, Joshua A.
    Rodriguez, Angel
    Bergman, Brandon K.
    Wang, Hui
    Ghimpeteanu, Gabriela
    Lee, Clare J.
    DIABETES CARE, 2023, 46 (12) : 2292 - 2299
  • [9] Effects of tirzepatide versus insulin glargine 100 U/mL on kidney outcomes in participants with type 2 diabetes in SURPASS-4
    Heerspink, H. J. L.
    Sattar, N.
    Pavo, I.
    Haupt, A.
    Duffin, K. L.
    Yang, Z.
    Wiese, R. J.
    Tuttle, K. R.
    Cherney, D. Z. I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S316 - S316
  • [10] Tirzepatide Reduces High-Sensitivity C-reactive Protein in Patients With Type 2 Diabetes and High Cardiovascular Risk: A Post Hoc Analysis of the SURPASS-4 Trial
    Bhatt, Deepak L.
    Wilson, Jonathan M.
    Wiese, Russell J.
    Yang, Zhengyu
    Duffin, Kevin L.
    Pavo, Imre
    CIRCULATION, 2023, 148
12345